Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

An operationalized workflow paradigm is presented and validated with pilot subject data. This approach is reproducible with a high concordance rate between individual readers (kappa 0.73 [confidence interval 0.59–0.87; P=<0.0001]) using a 5-point scale to assess [(18)F] labeled fluorodeoxyglucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Heertum, Ronald L, Scarimbolo, Robert, Wolodzko, John G, Klencke, Barbara, Messmann, Richard, Tunc, Feza, Sokol, Levi, Agarwal, Rajan, Strafaci, James A, O’Neal, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479259/
https://www.ncbi.nlm.nih.gov/pubmed/28670108
http://dx.doi.org/10.2147/DDDT.S136988
_version_ 1783245104679485440
author Van Heertum, Ronald L
Scarimbolo, Robert
Wolodzko, John G
Klencke, Barbara
Messmann, Richard
Tunc, Feza
Sokol, Levi
Agarwal, Rajan
Strafaci, James A
O’Neal, Michael
author_facet Van Heertum, Ronald L
Scarimbolo, Robert
Wolodzko, John G
Klencke, Barbara
Messmann, Richard
Tunc, Feza
Sokol, Levi
Agarwal, Rajan
Strafaci, James A
O’Neal, Michael
author_sort Van Heertum, Ronald L
collection PubMed
description An operationalized workflow paradigm is presented and validated with pilot subject data. This approach is reproducible with a high concordance rate between individual readers (kappa 0.73 [confidence interval 0.59–0.87; P=<0.0001]) using a 5-point scale to assess [(18)F] labeled fluorodeoxyglucose metabolic activity in lymphomatous lesions. These results suggest an operationally practical 5-point scale workflow paradigm for potential use in larger clinical trials evaluating lymphoma therapeutics.
format Online
Article
Text
id pubmed-5479259
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54792592017-06-30 Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials Van Heertum, Ronald L Scarimbolo, Robert Wolodzko, John G Klencke, Barbara Messmann, Richard Tunc, Feza Sokol, Levi Agarwal, Rajan Strafaci, James A O’Neal, Michael Drug Des Devel Ther Original Research An operationalized workflow paradigm is presented and validated with pilot subject data. This approach is reproducible with a high concordance rate between individual readers (kappa 0.73 [confidence interval 0.59–0.87; P=<0.0001]) using a 5-point scale to assess [(18)F] labeled fluorodeoxyglucose metabolic activity in lymphomatous lesions. These results suggest an operationally practical 5-point scale workflow paradigm for potential use in larger clinical trials evaluating lymphoma therapeutics. Dove Medical Press 2017-06-13 /pmc/articles/PMC5479259/ /pubmed/28670108 http://dx.doi.org/10.2147/DDDT.S136988 Text en © 2017 Van Heertum et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Van Heertum, Ronald L
Scarimbolo, Robert
Wolodzko, John G
Klencke, Barbara
Messmann, Richard
Tunc, Feza
Sokol, Levi
Agarwal, Rajan
Strafaci, James A
O’Neal, Michael
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
title Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
title_full Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
title_fullStr Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
title_full_unstemmed Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
title_short Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
title_sort lugano 2014 criteria for assessing fdg-pet/ct in lymphoma: an operational approach for clinical trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479259/
https://www.ncbi.nlm.nih.gov/pubmed/28670108
http://dx.doi.org/10.2147/DDDT.S136988
work_keys_str_mv AT vanheertumronaldl lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT scarimbolorobert lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT wolodzkojohng lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT klenckebarbara lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT messmannrichard lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT tuncfeza lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT sokollevi lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT agarwalrajan lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT strafacijamesa lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials
AT onealmichael lugano2014criteriaforassessingfdgpetctinlymphomaanoperationalapproachforclinicaltrials

Ejemplares similares